Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   HEPATITIS MONTHLY   MARCH 2011 , Volume 11 , Number 3 (32); Page(s) 191 To 194.
 
Paper: 

EPIDEMIOLOGICAL FEATURES OF PATIENTS INFECTED WITH HCV GENOTYPE 4 IN POLAND

 
 
Author(s):  CHLABICZ S.*, FLISIAK R., LAPINSKI T.W., KOWALCZUK O., WIERCINSKA DRAPALO A., PYTEL KROLCZUK B., GRZESZCZUK A., CHYCZEWSKI L., PANCEWICZ J.
 
* DEPARTMENT OF FAMILY MEDI¬CINE AND COMMUNITY NURSING, MIESZKA I 4 B 15-054 BIAŁYSTOK, POLAND
 
Abstract: 

Background: Hepatitis C genotype 4 (HCV-4) is considered to be rare outside northern Africa and southern Europe.
Objectives: To describe the epidemiological characteristics of patients infected with HCV-4 in Poland.
Patients and Methods: The study group included 290 patients with HCV-related chronic liver disease and intravenous drug users with HCV infection recruited in years 2002-2006 in Pod­laskie region, north-eastern Poland. In all cases, HCV infection was confirmed by HCV-RNA detection by qualitative nested RT-PCR. HCV genotype was determined by 5'UTR sequencing and comparison with known genotype-specific sequences.  
Results: HCV 4 was found in 45 (15.5%) of 290 HCV-infected and HCV RNA-positive individuals. 60% of HCV 4 infections occurred in intravenous drug users; 51% of HCV 4-infected patients were also HIV-positive. Among 119 patients whose source of infection was other than drug use, there were 16 (10.5%) HCV 4 cases. Seven (46%) of 13 HCV 4-positive and HIV-negative pa­tients who received combined antiviral treatment had sustained viral response.
Conclusions: HCV 4 exists in eastern Poland, and the infection is frequently related to intra­venous drug use and accompanied by HIV infection. HCV 4 also causes a proportion of non-drug-related HCV infections.

 
Keyword(s): GENOTYPES, HEPATITIS C, DRUG USERS
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 117
 
Latest on Blog
Enter SID Blog